One step prodrug trigger for targeted release of drugs

submit enquiry
Cancer cell ©iStockphoto
Cancer cell ©iStockphoto

University: University of Edinburgh

Sector(s): Life Sciences, Healthcare & Pharmaceuticals

About Opportunity:

A tetrazine small-molecule trigger for activating prodrugs has been developed. Active molecules, such as a therapeutic drug or imaging fluorophore, can be caged within a polymer nanoparticle for controlled release at a targeted site.

The Challenge

Many drugs cannot be taken directly as they are unstable under physiological conditions and/or toxic. Using a ‘prodrug’ is the common solution, where the drug is masked, and activated by de-masking at the target site. There is a general need for controlled-release drugs that offer a more effective dose and minimise side effects, particularly for cancer treatment. A promising recent approach has sought to exploit a bio-orthogonal reaction using tetrazine as the trigger to unmask the prodrug.

Technology

The vinyl group is small and chemically stable; active molecules with a vinyl ether mask are easier to prepare and less disruptive than current masking groups used with a tetrazine trigger. Custom designed tetrazines are stable under physiological conditions, and allow a controlled rate of reaction. Unmasking by tetrazine is also a one-step reaction, with no catalyst or biological species required, and the by-products are safe. Furthermore, masked molecules can be conjugated within a polymer nanoparticle with linkers that self-immolate upon reaction with tetrazine. This allows targeted and effective release of the active cargo at a specific site, such as a tumour.

Exemplification Data

Extensive in vitro data; for example, tetrazine-controlled release of Doxorubicin from a Polyethylene Glycol (PEG) nanoparticle to trigger cell death in an environment of prostate cancer cells.

Development Status: Comprehensive in vitro analysis

Key Benefits:

  • Controlled reactivity, and stable under physiological conditions
  • Exploits a simple bio-orthogonal release reaction with tetrazine
  • Selective release for controlled dose and enhanced cellular uptake
  • Medication is more effective and side-effects are reduced

Applications:

  • Delivery of therapeutic agents as prodrugs (e.g. Doxorubicin)
  • Medical imaging

IP Status:

A PCT patent application has been filed

Publication: Neumann et al.: Chem. Commun. 2016, 52, 11223 ChemBioChem 2017, 18, 91

The University of Edinburgh is seeking industry partners to license this technology and/or collaborate on further research development of the technology for commercial use.

Enquiry

Please enter your name.

Please enter the name of the company you work for.

Is your company an SME?

Please select the country you are in.

Please select what part of the UK you are in.

Please select from the following options.

Please enter your email address.

To help us process your enquiry faster please enter some details about the information you are interested in.

Words remaining:

Related Opportunities

  • Lab in a Pill

    Scientists at the University of Glasgow have pioneered a new sensor technology, Lab-in-a-Pill, that could have major impact on the cost and effectiveness of bowel cancer treatment.

    Expires: Created:
  • Thermoelectric Sensor

    The Thermoelectric Sensor technology is a Nano-Calorimetric Sensor which measures very small changes in temperature. The IP provides a route to making the most sensitive calorimetric measurements (with a resolution of 0.1 mK).

    Expires: Created:
  • Parkinson's Disease Model

    The University of Glasgow is offering an exciting new model for the evaluation of new treatments for Parkinsons disease

    Expires: Created:
  • Combination Treatment for MRSA Nasal Carriage and MRSA-infected Wounds

    The new treatment is a combination of a peptide (ranalexin) with bacteria cell wall-digesting protein (lysostaphin), which specifically targets and kills Staphylococcus aureus, including MRSA.

    Expires: Created:
  • Synergistic antifungal combination

    Candida species are a major cause of catheter-related nosocomial bloodstream infections. We have identified that the combination of an echinocandin antifungal with certain antimicrobial peptides results in potent, synergistic inhibition of yeast pathogens in vitro, so offering a potential combinatio...

    Expires: Created:

Alerts Signup

Sign up to our technology alerts and be the first to hear about any new technology opportunities from Scotland's universities


Register Now for University Technology.com Alerts


Search Filter

Share this page

Use the buttons below to share these technology opportunities on your favourite social networking site. You can also share them from inside the individual opportunity.